FDA National Priority Voucher (CNPV): Should You Apply?
Written byNeta Kela, PhDFounder & Managing Partner
Short answer: The FDA national priority voucher (CNPV) can compress the review of a complete NDA or BLA to roughly one to two months, but only if your CMC package, facilities and data are inspection-ready weeks before you file. It suits late-stage programs that clearly fit one of FDA's five national priorities. For most European sponsors still at pre-IND or early IND stage, the better move in 2026 is to build CNPV readiness into your FDA regulatory strategy now and apply once the package is near final.
What is the FDA national priority voucher?
The Commissioner's National Priority Voucher (CNPV) pilot is an FDA program launched in June 2025 that gives selected drugs and biologics an accelerated, team-based review. FDA's stated target is a decision within 1 to 2 months of filing, compared with 6 months or more under standard timelines. Reviews run through a multidisciplinary, "tumor board-style" meeting of senior FDA staff rather than a conventional sequential review.
The approval standard does not change. CNPV applications must meet the same statutory and regulatory requirements as any other NDA or BLA. What changes is speed, access and the intensity of sponsor engagement.
The first nine vouchers were announced on October 16, 2025. Independent trackers now count more than 20 vouchers across six award rounds, the most recent in spring 2026. FDA's program page lists 10 approvals as of August 26, 2026; one independent tracker counts 11.
Which programs qualify?
FDA selects products that advance at least one of five national priorities:
- Public health crisis response for urgent or emerging threats
- Innovative breakthrough therapies with novel mechanisms
- Large unmet medical needs where current options fall short
- Onshoring and supply chain resilience, including domestic manufacturing
- Affordability, meaning approaches that lower cost or improve access
The program covers NDAs, BLAs and certain manufacturing or efficacy supplements. Device-only applications are excluded. Sponsors submit a short statement of interest through FDA's online form on a rolling basis, and FDA review divisions can also nominate products already under review. A voucher can be granted at any development stage. Early-stage holders get more frequent FDA interactions until they file.
Vouchers are non-transferable, though they survive a change of ownership. FDA expects holders to start using the voucher within two years.
How fast are CNPV reviews in practice?
Faster than standard, but not always as fast as the headline. Verified examples:
- Hernexeos (zongertinib), HER2-mutant NSCLC: approved February 26, 2026, 44 days after filing.
- Bizengri (zenocutuzumab), NRG1 fusion cholangiocarcinoma: approved May 8, 2026, the program's seventh approval.
- Lipfendra (enlicitide), the first oral PCSK9 inhibitor: approved July 17, 2026. The application was initiated in February, so the full cycle ran about five months.
- Rasonque (daraxonrasib), metastatic pancreatic cancer: approved August 26, 2026, about 6.5 months ahead of its goal date.
The pattern: the clock FDA quotes starts at a complete filing. The work that makes a one-to-two-month review possible happens in the 60 to 120 days before that, through rolling CMC and labeling submissions, pre-identified facilities and pre-scheduled inspections. Brookings analysts estimate realistic end-to-end timelines at 120 to 150 days once that pre-submission phase is counted.
How does CNPV compare with other FDA expedited programs?
| Program | Legal basis | What you get | Typical review clock | Transferable? | Best fit |
|---|---|---|---|---|---|
| CNPV | FDA pilot (no specific statute) | Team-based review, rapid FDA communication, rolling review | Target 1 to 2 months after complete filing | No | Late-stage programs that fit a national priority and have CMC ready |
| Breakthrough Therapy | FDASIA 2012 | Intensive FDA guidance from Phase 1, senior engagement, rolling review | Standard or priority clock (6 or 10 months) | No | Early clinical evidence of substantial improvement on a serious condition |
| Fast Track | FDAMA 1997 | More frequent meetings, rolling review | Standard or priority clock | No | Serious condition with unmet need, from preclinical onward |
| Priority Review | PDUFA 1992 | Shorter review goal at filing | 6 months (vs. 10 standard) | No | Significant improvement in safety or efficacy |
| Rare Pediatric Disease PRV | FD&C Act, reauthorized through Sept 2029 | Voucher redeemable for priority review on any later application | 6 months on the redeemed application | Yes, can be sold | Approved rare pediatric disease products; monetizable asset |
These programs stack. Rasonque, for example, held Breakthrough Therapy and Orphan designations and used Real-Time Oncology Review alongside its CNPV.
What are the risks and criticisms?
Sponsors should go in with eyes open:
- No congressional authorization. Lawmakers, including Rep. Frank Pallone and Sen. Bernie Sanders, have questioned the program's legal footing. A pilot created by FDA can be changed or ended by FDA.
- Transparency. Selection criteria are broad, and several vouchers followed drug pricing agreements with the White House. In July 2026, PhRMA asked FDA to run notice-and-comment rulemaking on eligibility and selection; Public Citizen urged a pause.
- Leadership change. Commissioner Marty Makary, who created the program, resigned in May 2026. Approvals have continued since, and FDA held a public hearing on the pilot in June 2026, but the rules may shift.
- Compressed-review risk. A one-to-two-month window leaves little room to resolve deficiencies. FDA expects responses within 24 to 48 hours, limits applications to roughly two or three manufacturing sites, and can move a weak application back to a standard clock.
What must EU sponsors have ready before applying?
European sponsors face two extra constraints: foreign inspections and distance from FDA working hours. FDA's own guidance stretches the pre-submission period from about 60 days to about 120 days when foreign inspections are expected.
CMC. This is where most programs will fail the CNPV test. FDA expects CMC data and draft labeling submitted on a rolling basis at least 60 days before the final application. Process validation, stability data and specifications need to be close to final. Our CMC strategy work starts here.
Regulatory status. You need an active IND and a clear record of FDA interactions. If you have not yet held a pre-IND meeting, start there. A voucher granted pre-IND buys communication, not speed.
US manufacturing angle. Onshoring is one of the five priorities. A credible US manufacturing or fill-finish plan, or a US CDMO partnership, strengthens a statement of interest and simplifies inspections. See our guide to US CDMO and CRO selection under BIOSECURE and FDA PreCheck.
Team capacity. You need people who can answer FDA within two business days, US time. Many EU biotechs fill this gap by embedding senior US regulatory and CMC operators through PXM Operate, including former FDA reviewers via our partners.
CNPV readiness checklist
- Program maps clearly to at least one of the five national priorities, with evidence
- Active IND with documented FDA interactions (pre-IND, End-of-Phase 2)
- Pivotal data in hand or reading out within 6 to 12 months
- CMC package near final: validation, stability, specifications
- Manufacturing limited to two or three identified sites, inspection-ready
- Clinical sites identified for BIMO inspection
- Draft labeling prepared for rolling submission
- US manufacturing or supply chain story documented, if relevant
- Team able to respond to FDA within 24 to 48 hours in US hours
- Other expedited designations (Breakthrough, Fast Track, Orphan) assessed in parallel
FAQ
Can a non-US company receive a national priority voucher?
FDA's published criteria do not restrict CNPV to US sponsors. Foreign sponsors should plan for a longer pre-submission period (about 120 days) because of foreign inspections, and a US manufacturing angle can strengthen the case.
Does a CNPV lower the bar for approval?
No. CNPV applications must meet the same statutory and regulatory standards as any NDA or BLA. Only the process and timeline change.
Can I sell or transfer a CNPV?
No. Unlike the rare pediatric disease PRV, a CNPV is non-transferable, though it remains valid if the company is acquired.
When should we submit a statement of interest?
Submissions are rolling. The voucher has the most value once pivotal data and CMC are close to final, because the speed benefit applies at filing. Earlier statements can still secure enhanced FDA communication during development.
Show PXM what you are building
PXM embeds senior regulatory, CMC and clinical operators inside European biotech teams to build FDA regulatory strategy, from pre-IND meeting to approval. Explore our FDA regulatory affairs practice, or show PXM what you are building.
Sources
- FDA, Commissioner's National Priority Voucher (CNPV) Pilot Program: https://www.fda.gov/industry/commissioners-national-priority-voucher-cnpv-pilot-program
- FDA, FAQs: Commissioner's National Priority Voucher Pilot Program: https://www.fda.gov/news-events/press-announcements/faqs-commissioners-national-priority-voucher-pilot-program
- Federal Register, CNPV Pilot Program public hearing notice (2026-05573): https://public-inspection.federalregister.gov/2026-05573.pdf
- FDA, FDA Grants Second Approval under the National Priority Voucher Pilot Program: https://www.fda.gov/news-events/press-announcements/fda-grants-second-approval-under-national-priority-voucher-pilot-program
- FDA, FDA Grants Seventh Approval under the National Priority Voucher Pilot Program: https://www.fda.gov/news-events/press-announcements/fda-grants-seventh-approval-under-national-priority-voucher-pilot-program
- FDA, FDA Approves First Oral PCSK9 Inhibitor: https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol
- FDA, FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma
- BioPharma Dive, Merck wins first approval of a PCSK9 cholesterol pill: https://www.biopharmadive.com/news/merck-lipfrendra-enlicitide-fda-approve-voucher-pcsk9/825377/
- PRV Watch, CNPV Dashboard: https://prvwatch.com/cnpv-dashboard
- Brookings, FDA's new Commissioner's National Priority Voucher has lofty goals. Can it deliver?: https://www.brookings.edu/articles/fdas-new-commissioners-national-priority-voucher-has-lofty-goals-can-it-deliver
- Fierce Biotech, Lawmakers probe FDA's new priority voucher program: https://www.fiercebiotech.com/biotech/questions-swirl-over-fdas-national-priority-voucher-program-2-lawmakers-push-answers
- RAPS, Industry groups press FDA for transparency, next steps for CNPV program: https://www.raps.org/resource/industry-groups-ask-fda-for-transparency-cnpv.html
- Fierce Pharma, FDA's rare pediatric disease voucher program revived by 2026 government funding bill: https://www.fiercepharma.com/pharma/fdas-rare-pediatric-disease-voucher-program-revived-2026-government-funding-bill
Frequently Asked Questions
How PXM Helps With This
FDA Regulatory Readiness & Submission Support
Pathway strategy, FDA meeting preparation, submissions, and agency responses.
IND-Enabling Regulatory Strategy
Pre-IND strategy, nonclinical package design, and IND readiness planning.
CMC Strategy & Manufacturing Readiness
CMC roadmaps, CDMO selection, comparability strategy, and CMC submissions.
Related
Part of FDA & CMC Readiness. Start from the pillar: Operate practice, FDA Regulatory Readiness, CMC & Manufacturing, FDA Expedited Pathways
Your CDMO Just Became a Regulatory Risk: BIOSECURE and FDA PreCheck Explained
The BIOSECURE Act is law and the FDA's PreCheck pilot has named its first participants. Both change how EU biotechs should screen, select, and oversee US CDMOs and CROs.
How to Prepare for an FDA Pre-IND Meeting (and What Most Teams Get Wrong)
A pre-IND meeting is the cheapest regulatory advice a biotech will ever get, and the most commonly wasted. What to ask, what to include in the briefing book, and where teams lose the value.
IND-Enabling Studies: What a First-in-Human Package Actually Requires
What IND-enabling studies are, which ones the FDA expects before first-in-human, how long the package takes, and the sequencing decisions that quietly determine your filing date.
Get notified when we publish new funding and regulatory guides
Practical guidance on FDA and EMA strategy, CMC readiness, and non-dilutive funding — sent only when there is something worth reading.